In the ICU, where patients already experience severe metabolic stress and muscle breakdown, clinicians have worried that these medications might quietly worsen outcomes
You are measuring your impatience
GLP-1 receptor agonists act primarily by enhancing postprandial insulin secretion and suppressing glucagon release, leading to improved glycemic control ( Emerging evidence suggests that GLP-1 receptors are not confined to pancreatic islets but are also expressed in cardiomyocytes and vascular endothelial cells ( GLP-1 receptor activation induces vasodilation through various pathways
This is an opportunity to find a new way forward to advance medical innovation by leveraging real-world data, instead of relying on expensive and time-consuming trials whose limitations are growing more and more apparent
Zavacki AM, Mansell JB, Chung M, Klimovitsky B, Harney JW, Berry MJ